Table of Contents
Contents
EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Discontinued Agreements
- Manufacturing/R&D Infrastructure
- Products/R&D
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions/Outlook
THERAPEUTIC AREA FOCUS
R&D PIPELINE
CENTRAL NERVOUS SYSTEM
- Marketed Products
- Campral
- Lexapro
- Namenda
- Savella
- Others
- R&D Projects
- F2695
- mGLUR1/5 antagonists
- Neramexane
- Cariprazine
- RGH-896
- Growth Forecast
CARDIOVASCULAR
- Marketed Products
- R&D Projects
- Growth Forecast
OTHER
- Marketed Products
- R&D Projects
- Aclidinium
- Ceftaroline
- Linaclotide acetate
- ME1036
- Oglemilast
- Growth Forecast
APPENDIX 1 - FINANCIAL PERFORMANCE
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREMENTS
- Almirall Prodesfarma SA
- Aurigene Discovery Technologies Ltd
- BTG Ltd
- Cypress Bioscience Inc
- Daiichi Sankyo
- Gedeon Richter Ltd
- Glenmark Pharmaceuticals Ltd
- INO Therapeutics
- Ironwood Pharmaceuticals Inc
- Lundbeck
- Merck KGaA
- Merz Pharma GmbH & Co KGaA
- Mylan Laboratories Inc
- Novexel
- Pierre Fabre Medicament
- Phenomix Co
- Recordati
- Procter & Gamble
- Samaritan Pharmaceuticals Inc
APPENDIX 4 - INFRASTRUCTURE
- Research And Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES
APPENDIX 6 - PRODUCT INDEX
|
Related Report
|
View Cart
